Desenvolvimento de micropartículas teragnósticas de Dacarbazina como dispositivo para liberação local e controlada para melanoma metastático

• Autor(a) principal: Rosa, Thiago Goulart
• Data de Publicação: 2017
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da UERJ
• Texto Completo: http://www.bdtd.uerj.br/handle/1/16312
• topic: Cancer; Nuclear Medicine; Microparticles; Radiopharmaceuticals; Câncer; Medicina Nuclear; Micropartículas; Radiofármaco; Medicina nuclear; Câncer Imagens; Melanoma; Metástase; Metástase; Neoplasias; CNPQ::CIENCIAS DA SAUDE::FARMACIA

Metastatic melanoma (MM) is an aggressive, difficult treatment and deadly type of cancer. Although its incidence is low, the number is increasing year after year. The treatment of metastatic melanoma has limitations beyond it s a long and a low therapeutic arsenal. Besides, the drugs used to have a rate of humble success due the characteristics of this tumor. Nevertheless, the diagnosing of this cancer is always made by an invasive methodology, mostly biopsy. In this direction we developed and dacarbazine microparticle that may be labeled with 99mTc and 223Ra for both use: diagnostic and therapy. The results showed that a 559nm microparticle were obtained with a spherical shape. The results in animals (mice) inducted with metastatic melanoma demonstrated that the microparticle were able to reach the tumor with a high rate (20%). Also demonstrated that the microparticles had a low recognition by the Mononuclear Phagocytic System and a high affinity by the blood proteins, increasing the circulating time. Also, was possible to observe the renal clearance. The cytotoxicity demonstrated the safe use. All this data corroborates the use as a theragnostic agent for imaging (diagnosing) and therapy of MM. The imaging possibility is of great importance because it can replace the biopsy examination.